Burning Rock Biotech Ltd BNR
Medical Specialities · IPO 2020 · data as of November 13, 2026
Burning Rock Biotech Ltd (BNR) is a healthcare company listed in the US with a market value of about $140M. In fiscal year 2025 it had revenue of $77M and net income of -$8M, a net margin of -10.3%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 3% a year, a 5-year average ROIC of -43%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 81% below the current price.
About Burning Rock Biotech
Burning Rock Biotech is listed in the US and classified in medical specialities, IPO year 2020. Revenue went from $66M in 2020 to $77M in 2025, growth of about 3.2% a year. It was profitable in 0 of the last 6 years in our data. It spends 31% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | $77M | $71M | $76M | $82M | $80M | $66M |
| Net income | -$8M | -$47M | -$92M | -$141M | -$125M | -$62M |
| Free cash flow | -$5M | -$13M | -$37M | -$75M | -$107M | -$21M |
| EPS (diluted) | $-0.75 | $-4.50 | $-8.73 | $-13.35 | $-11.85 | $-5.92 |
| Net margin | -10.3% | -67.2% | -121.6% | -172.4% | -156.9% | -94.7% |
| ROIC | -7.5% | -44.6% | -67.7% | -64.1% | -32.6% | -17.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Burning Rock Biotech stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 81% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Burning Rock Biotech pay a dividend?
Not currently.
Is Burning Rock Biotech a good stock to buy?
We do not give buy or sell advice. Burning Rock Biotech scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.